Navigation Links
InNexus Biotechnology Receives Patent Grants in Europe
Date:10/30/2008

European patent grants.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in- house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
2. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
3. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
4. InNexus Biotechnology Strengthens Patent Team With New Leadership
5. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
6. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
7. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
8. TechConnect World 2009 Matches Tomorrows Technology Solutions with Todays Business Needs for Clean-Technology, Biotechnology and Nanotechnology
9. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
10. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
11. SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... (PRWEB) March 05, 2015 Plant disease ... this summer at the Annual Meeting of The American ... to be released online now at APSnet.org/meet . ... for the meeting, to be held August 1-5, 2015 ... Special Sessions, Field Trips, Workshops, and committee meetings, all ...
(Date:3/5/2015)... 2015 Bi-Biomics today announced a ... stain additive. The improvement in histological quality provided ... present in all daughter cells. , After processing ... was analyzed at 1000-1600x using light microscopy. ... in all daughter cells displayed predominant binary features ...
(Date:3/5/2015)... SAN DIEGO and TORONTO ... APTO, TSX: APS), a clinical-stage company developing new therapeutics ... cancer, today announced that William G. Rice , ... at the upcoming 27th Annual ROTH Conference on Tuesday, ... the The Ritz Carlton, Laguna Niguel, CA. ...
(Date:3/5/2015)... Mar. 05, 2015 Research and Markets ... "Mature Biotech Outlook 2015: New Therapy Ventures Pave ... All biotech companies - Gilead (GILD), ... past year, have given a positive return and hence ... been able to select therapy/niche indication where the high ...
Breaking Biology Technology:American Phytopathological Society Announces Annual Meeting Daily Schedule 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3
... NEW YORK, Sept. 8 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, ... "AOBO"), a pharmaceutical,company dedicated to improving health through the ... and over the counter ("OTC"),products, today announced the Company,s ... -- Morgan Stanley Healthcare Corporate Day, to be held ...
... , , , ... Inc., the leading systems biology tools company, announced today that ... MetaCore. Proteostasis Therapeutics is the first company dedicated to ... the body,s Proteostasis Network. The Proteostasis Network maintains the ...
... ... of radical technological change--a scene sometimes called "transhumanism"--is going into print with its fourth ... issue is available digitally now. , ... San Jose, CA (PRWEB) September 8, 2009 -- The Fall 2009 ...
Cached Biology Technology:American Oriental Bioengineering Announces September Investor Conferences Participation 2GeneGo Licenses MetaCore to Proteostasis Therapeutics 2New Transhumanist Magazine is Going into Print - Digital Edition is Available Now 2
(Date:2/12/2015)... , Feb. 12, 2015   MedNet ... specializing in clinical study management systems, has recently ... , further distinguishing iMedNet ... Research Organizations (CROs) and healthcare consultants.  Building on ... prospective customer referrals and numerous co-marketing opportunities), MedNet,s ...
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... Engineering researchers have discovered a new way to ... found in plants. , Reporting in the June ... James Dumesic and colleagues detail a four-phase catalytic ... can be converted to sulfur-free liquid alkanes resulting ...
... examples of bacteria that can thrive in extreme situations---surviving ... online in the Journal of the American Chemical Society ... some bugs manage to do that: by harnessing other ... the toxins they live on. , Such insights could ...
... have discovered a novel strategy by which the bacterium ... the effects of antibiotics known as fluoroquinolones. The finding ... coli, are rapidly becoming resistant to fluoroquinolones. , The ... Blanchard, the Dan Danciger Professor of Biochemistry at the ...
Cached Biology News:Green diesel: New process makes liquid transportation fuel from plants 2A radical solution for environmental pollution 2Einstein researchers identify new way that bacteria develop resistance to antibiotics 2
... Adept CE 4100 high pressure pump ... precision, with software drive compensation, reducing pulsing ... are selectable in 0.001mL steps. , The ... and bio-compatible., Pumps may be programmed from ...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
Monoclonal antibodies conjugated with rhodamine...
Biology Products: